Endocrine Abstracts

Background: Despite global guidelines recommending initiation of SGLT2i drugs like dapagliflozin in type 2 diabetes (T2DM) patients with cardiovascular (CV) or renal risk, its clinical translation is still lacking in India.Objective: To understand clinicians’ perspectives regarding the association of CV risk and T2DM in Indian patients, and the need for the use of combination therapies with dapagliflozin in T2DM patients, in Indian clinical practice...